A H Briggs
Affiliation: University of Oxford
- New methods of analysing cost effectivenessAndrew H Briggs
BMJ 335:622-3. 2007
- The death of cost-minimization analysis?A H Briggs
Health Economics Research Centre, University of Oxford, UK
Health Econ 10:179-84. 2001..The first shows a situation where analysts might be tempted (inappropriately) to employ CMA rather than CEA. The second illustrates one of the rare circumstances in which CMA may be justified as a legitimate form of analysis...
- Confidence intervals or surfaces? Uncertainty on the cost-effectiveness planeA Briggs
Health Economics Research Centre, Institute of Health Sciences, University of Oxford, Headington, UK
Health Econ 7:723-40. 1998..This approach is consistent with decision-making on the cost-effectiveness plane and with the cost-effectiveness acceptability curve approach to presenting uncertainty due to sampling variation in stochastic cost-effectiveness analyses...
- Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian frameworkAndrew H Briggs
Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Headington, Oxford OX3 7LF, United Kingdom
Med Decis Making 23:341-50. 2003..Furthermore, they demonstrate that by adopting a Bayesian approach, the problem of observing zero counts for transitions of interest can be overcome...
- Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux diseaseAndrew H Briggs
Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Headington, United Kingdom
Med Decis Making 22:290-308. 2002..It is argued that probabilistic analyses should be encouraged because they have potential to quantify the strength of evidence in favor of particular treatment choices...
- Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studiesAndrew H Briggs
Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford OX3 7LF, United Kingdom
Annu Rev Public Health 23:377-401. 2002..Finally, we outline some of the challenges for future research in this area-particularly in relation to the appropriate use of Bayesian methods and methods for analyzing costs that are typically skewed and often incomplete...
- Handling uncertainty in cost-effectiveness modelsA H Briggs
Health Economics Research Centre, University of Oxford, England
Pharmacoeconomics 17:479-500. 2000..Such probabilistic analyses are related to parameter uncertainty. In addition, modelling uncertainty is likely to add a further layer of uncertainty to the results of particular analyses...
- Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulationA H Briggs
Health Economics Research Centre, Oxford Institute of Health Sciences and Nuffield College, University of Oxford, U K
Stat Med 18:3245-62. 1999..However, where it is suspected that the sampling distribution is skewed, normal approximation methods produce particularly poor results and should be avoided...
- An introduction to Markov modelling for economic evaluationA Briggs
Health Economics Research Centre, Institute of Health Sciences, University of Oxford, England
Pharmacoeconomics 13:397-409. 1998..Analysts should be aware of the limitations of Markov models, particularly the Markovian assumption, although the adept modeller will often find ways around this problem...
- A Bayesian approach to stochastic cost-effectiveness analysisA H Briggs
Health Economics Research Centre, University of Oxford, Headington, UK
Health Econ 8:257-61. 1999..Although it is argued that their interpretation as the probability that an intervention is cost-effective given the data requires a Bayesian interpretation, this should generate no misgivings for the frequentist...
- Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UKH E Campbell
Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, Oxford OX3 7LF, UK
Br J Cancer 103:776-86. 2010....
- Statistical approaches to handling uncertainty in health economic evaluationAndrew H Briggs
Health Economics Research Centre, Department of Public Health, University of Oxford, UK
Eur J Gastroenterol Hepatol 16:551-61. 2004..The second example is a secondary study of the management of gastro-oesophageal reflux disease symptoms which considered six potential strategies simultaneously...
- Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysisJeffrey S Hoch
Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada
Health Econ 11:415-30. 2002....
- A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial resultsShelby D Reed
Pharmaceutical Outcomes Research and Policy Program, University of Washington, USA
Med Decis Making 23:252-64. 2003..Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations...
- Development of an economic model to assess the cost effectiveness of asthma management strategiesMartin J Price
Global Health Outcomes, GlaxoSmithKline Research and Development, Greenford, Middlesex, United Kingdom
Pharmacoeconomics 20:183-94. 2002..The model's flexible yet standardised framework permits the cost effectiveness of alternative asthma management strategies in different healthcare settings to be established...
- Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel modelsAndrea Manca
Centre for Health Economics, University of York, UK
Health Econ 14:471-85. 2005....
- Pharmacoeconomics in COPD: lessons for the futureHelen J Starkie
Public Health and Health Policy, University of Glasgow, Glasgow, UK
Int J Chron Obstruct Pulmon Dis 3:71-88. 2008....
- Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing dataAndrew H Briggs
Public Health and Health Policy, University of Glasgow, Glasgow, UK
Value Health 9:227-35. 2006....
- Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organizationYves M Gagnon
Oxford Outcomes Ltd, 450-688 West Hastings Street, Vancouver, BC, Canada
Respir Med 99:1534-45. 2005..If the impact on survival seen in these trials compares to that seen in observational studies, LABA and the combination treatment are likely to be cost-effective in the United States...
- Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary diseaseMichael Spencer
Global Health Outcomes, GlaxoSmithKline Research and Development, Greenford, Middlesex, UK
Pharmacoeconomics 23:619-37. 2005....
- Conducting economic evaluations alongside multinational clinical trials: toward a research consensusShelby D Reed
Center for Clinical and Genetic Economics, Duke University Medical Centre, Durham, NC, USA
Am Heart J 149:434-43. 2005..Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies...
- Treatment costs in Canada of health conditions resulting from chronic hepatitis B infectionYves M Gagnon
Occam Research and Consulting Inc, Canada
J Clin Gastroenterol 38:S179-86. 2004..To estimate resource use and expected annual cost of care for subjects with chronic hepatitis B and resulting complications in Canada...
- Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness dataAndrew R Willan
Program in Population Health Sciences, Hospital for Sick Children, and Department of Public Health Services, University of Toronto, ON, Canada
Health Econ 13:461-75. 2004..Furthermore, the method can exhibit efficiency gains over unrelated ordinary least squares regression...
- A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censoredGordon Blackhouse
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
Med Decis Making 22:173-7. 2002..The authors address the joint problem of estimating ICER precision in the presence of censoring...
- A glossary of economic termsNaoki Chiba
Eur J Gastroenterol Hepatol 16:563-5. 2004